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Summary
Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or 
peripheral T-cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on the 
National Cancer Institute 1312 trial, demonstrating long-term disease control and the ability to 
retreat patients relapsing off-therapy. In all, 84 patients with CTCL and 47 with PTCL were 
enrolled. Responses occurred early, were clinically meaningful and of very long duration in some 
cases. Notably, patients with PTCL receiving romidepsin as third-line therapy or later had a 
comparable response rate (32%) of similar duration as the total population (38%). Eight patients 
had treatment breaks of 3.5 months to 10 years; in four of six patients, re-initiation of treatment 
led to disease regression. Safety data show slightly greater haematological and constitutional 
toxicity in PTCL. cDNA microarray studies show unique individual gene expression profiles, 
minimal overlap between patients, and both induction and repression of gene expression that 
reversed within 24 h. These data argue against cell death occurring as a result of an epigenetics-
mediated gene induction programme. Together this work supports the safety and activity of 
romidepsin in T-cell lymphoma, but suggests a complex mechanism of action.
Keywords
Epigenetic therapy; HDAC inhibitor; Romidepsin; T-cell lymphoma; Chromatin
Introduction
The epigenetic agents romidepsin (depsipeptide, FK228, FR 901228) and vorinostat are 
histone deacetylase (HDAC) inhibitors approved for use in T-cell lymphoma (Coiffier, et al 
2012, Duvic, et al 2007, Olsen, et al 2007, Piekarz, et al 2009, Piekarz, et al 2011, 
Whittaker, et al 2010). HDAC inhibitors increase global histone acetylation in cancer cells 
and promote T-cell apoptosis (Shao, et al 2010, Zhang, et al 2005). While studies have 
begun to identify the molecular basis of the various subtypes of mature T-cell lymphomas 
(Campbell, et al 2010, Ferrara, et al 2013, Lemonnier, et al 2012, McKenzie, et al 2012, 
Palomero, et al 2014), responses to romidepsin and vorinostat have been reported across the 
entire disease spectrum, without regard to subtype. The precise mechanism underlying 
activity against T-cell lymphoma has yet to be determined, and multiple biological effects 
have been invoked. Leading candidate mechanisms include the induction of genes that 
promote apoptosis, DNA damage due to acetylation-induced double-strand breaks and 
reactive oxygen species release, and aberrant kinetochore assembly (Bolden, et al 2013, 
Conti, et al 2010, Robbins, et al 2005, Robert and Rassool 2012). Vorinostat and romidepsin 
are from different chemical classes, have different histone deacetylase affinities and are 
administered in different schedules - lower potency vorinostat administered on a continuous 
schedule and higher potency romidepsin given intermittently – yielding some differences in 
biological and clinical activity. Responses observed in a National Cancer Institute (NCI) 
phase 1 trial conducted with romidepsin provided the impetus to assess HDAC inhibitor 
efficacy in patients with cutaneous T-cell lymphoma (CTCL) and peripheral T-cell 
lymphoma (PTCL) (Piekarz, et al 2001); data from subsequent preclinical models supported 
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those observations of activity (Chakraborty, et al 2013, Piekarz, et al 2004, Tiffon, et al 
2011).
Regulatory approval for romidepsin from the United States Food and Drug Administration 
(FDA) was first received for CTCL based on two clinical trials – GPI-04-0001 and 
NCI1312. Both trials were multi-institutional, international, non-randomized Phase II trials, 
with the GPI-04-0001 study sponsored by Gloucester Pharmaceuticals Inc. (GPI). Response 
rates were 34 and 35%, respectively, with median response durations of 15 and 13.7 months, 
respectively (Piekarz, et al 2009, Whittaker, et al 2010). Of potentially greater clinical 
significance, activity was also demonstrated in patients with PTCL, an aggressive form of 
lymphoma with lower response rates and higher relapse rates that traditionally has been 
treated with therapies developed for B-cell lymphomas. Data submitted in support of 
regulatory approval for PTCL were based on two trials – GPI-06-0002 and NCI1312. 
Response rates were 29% and 38%, respectively, with median durations of 17 and 9 months 
(Coiffier, et al 2012, Piekarz, et al 2011). A recent analysis of the GPI study updated the 
median response duration to 28 months (Coiffier, et al 2014). Accelerated approval was 
accorded in PTCL and the required follow-up trials are in progress.
Herein, we report results from the combined NCI1312 data set, focusing on analyses that 
were not presented in earlier publications, including long-term outcome and correlative data. 
The clinical data are considered together with the correlative studies to generate new 
insights regarding the mechanism of HDAC inhibitor action.
Patients and Methods
Study Design and Treatment Plan
NCI1312 (NCT00007345 at http://clinicaltrials.gov/), a prospective, non-randomized Phase 
II trial evaluating the safety and efficacy of romidepsin was conducted at 12 sites in the 
United States and Australia. The protocol underwent Institutional Review Board review at 
all participating sites. The trial was conducted essentially as an adaptive trial, with cohorts 
being added by amendment after efficacy was demonstrated, to confirm response in a 
broader patient population (Supplementary Figure 1). Patients with relapsed, refractory or 
advanced CTCL or PTCL meeting standard eligibility criteria were enrolled in one of 7 
cohorts, based on subtype and extent of prior therapy. The study was initially designed as a 
two-cohort study of CTCL and PTCL in patients previously treated with 2 or fewer prior 
cytotoxic chemotherapy regimens. As the clear efficacy signal emerged, cohorts for patients 
with more than two prior therapies, patients with more atypical forms of T-cell lymphoma 
and patients previously treated with vorinostat were added. Following discussions with the 
FDA the decision was made to open the study at additional sites and to reproduce the 
efficacy data in CTCL with the addition of a replicate cohort. Subsequently, data from the 
various cohorts were combined for regulatory submission. Results for CTCL and PTCL 
were reported separately (Piekarz, et al 2009, Piekarz, et al 2011).
Administered initially on a day-1 and -5 schedule, this was amended after the first 5 patients 
to 14 mg/m2 over 4 h on days 1, 8 and 15 of a 28-day cycle (Marshall, et al 2002, Sandor, et 
al 2002). Doses were reduced, per protocol guidelines, from 14 mg/m2 to 10.5 mg/m2 and to 
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8 mg/m2 for patients presenting with an absolute neutrophil count less than 0.5 x 109 cells/l, 
or platelet count between 50 and 75 x 109 cells/l. Doses were held for counts less than these 
or for grade 3 or higher non-haematological toxicity.
Safety Assessments and Supportive Care
Toxicities were scored according to the NCI Common Toxicity Criteria version 2.0 http://
ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/
ctcmanual_v4_10-4-99.pdf. All adverse events, regardless of clinical significance or 
attribution, were captured, including laboratory abnormalities. Cardiac safety evaluations led 
to the monitoring of potassium and magnesium during the study, with a standardized 
replacement schema to achieve serum magnesium and potassium levels over 0.85 mmol/l 
and 4.0 mmol/l, respectively, prior to romidepsin administration (Grant, et al 2010, Noonan, 
et al 2013, Piekarz, et al 2006). The protocol excluded medications known to interfere with 
CYP3A4 metabolism, because romidepsin is metabolized in part by CYP3A4 (Shiraga, et al 
2005), and those known to prolong the QTc interval. Prophylactic antiemetics were 
administered, with granisetron the antiemetic of choice. Central lines were avoided in CTCL 
patients with widespread skin involvement; if required, whirlpool baths with Dakin’s 
solution were used to reduce skin colonization prior to line placement (Frye, et al 2012), 
prophylactic antibiotics were administered while in place, and lines were discontinued 
between doses.
Efficacy Assessment and Response Criteria
For CTCL, a rigorous composite assessment was employed with uni-dimensional 
measurements of skin and visceral disease sites obtained and assessed by Response 
Evaluation Criteria in Solid Tumours (RECIST) (Piekarz et al 2009; Therasse et al 2000). 
Lymph node disease was assessed bi-dimensionally using International Working Group 
(IWG) criteria (Cheson, et al 1999). Bone marrow involvement, as recommended by IWG 
criteria, was scored present or absent. Generalized erythroderma was scored present or 
absent. Presence of circulating malignant T-cells ascertained by flow cytometry was scored 
present or absent. Complete response (CR) required clearing of all known disease sites. 
Partial response (PR) required documented response in skin (≥30% per RECIST) or lymph 
nodes (≥50% per IWG), with response in both compartments for a determination of PR. 
IWG guidelines (Cheson, et al 1999) were used to assess patients with PTCL.
Statistical Methods
Efficacy Data—Duration of response was determined from the date response was noted 
until the disease was no longer considered to be responding. Kaplan-Meier analyses 
provided the median duration of response.
Adverse Event Analysis—For each of the 34 toxicities observed in at least 10% of 
patients, the worst grade for each patient was noted (grade 0 events were calculated by 
subtraction for each toxicity and subtype). In cases with only two toxicity grades for 
comparison (five cases), Fisher’s exact test was used. For comparing the distribution of 
toxicity grades in the majority of cases, which were constructed as 2 x C ordered tables, an 
exact Cochran-Armitage trend test was used to compare the distributions. In view of the 
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large number of tests performed, we only refer to those with p-values <0.01 as statistically 
significant, with those for which 0.01 < p < 0.05 considered trends.
cDNA Array Analysis—Peripheral blood mononuclear cells from patients with 
circulating tumour cells were obtained before infusion (pre), and at 4 and 24 h after start of 
the infusion of the first cycle of treatment. Samples were hybridized on Illumina WG-8v2 
human whole-genome bead arrays using a constant amount (400 ng) of total RNA at the 
Wistar Institute Genomics facility. Illumina BeadStudio v.3.0 software was used to export 
expression levels and detection P values for each probe of each sample. Array data were 
quantile normalized, log2 transformed and filtered to remove non-informative probes. 
Principal component analysis (PCA), heat maps and unsupervised hierarchical clustering 
were performed in Qlucore Omics Explorer v.3.0 (Qlucore AB, Lund, Sweden). Data were 
previously submitted to the Gene Expression Omnibus [GEO] with accession number: 
GSE45405 (Chakraborty, et al 2013).
Results
Patients and Romidepsin Administration
As shown in Table I, 131 patients were enrolled, 84 with CTCL and 47 with PTCL, with a 
range of mature, post-thymic lymphoma subtypes, as previously reported (Piekarz, et al 
2011). Most patients had an Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 or 1. More men than women (57 vs. 27) with CTCL were enrolled, with a more 
equal distribution in those with PTCL. Median age (59 years) and age range in the two 
groups were comparable.
Among the 131 patients, 3404 doses of romidepsin were administered in 1214 cycles (Table 
II). The median number of cycles administered was 4.5 (1 – 79) for CTCL and 3 (1 – 83) for 
PTCL. In all, 75% of doses administered were at the protocol-prescribed dose or higher: at 
14 mg/m2 (67%, 2279 doses) and at 17.5 mg/m2 (8%, 286 doses). The remaining 24.6% of 
doses were reduced (839 doses) and only 1.4% or 47 doses were held. Doses were more 
likely to be reduced in the PTCL population (38%) than the CTCL population (16%). We 
assessed the number of “reductions from the immediate prior dose” to avoid confusion with 
doses that were consistently reduced to maintain tolerability. At 6% (3% for CTCL and 11% 
for PTCL), this observation indicated that once a dose of 10.5 mg/m2 was instituted, patients 
usually tolerated romidepsin without further need for dose reduction.
Efficacy Data for CTCL and PTCL
Updated response data for patients with CTCL are reported in Table III, including 84 
patients enrolled with CTCL. The overall response rate (ORR) of 33% is comparable to that 
previously reported for both the NCI and the GPI trials (Piekarz, et al 2009, Whittaker, et al 
2010). Patients with response had noticeable improvement after a few doses; the median 
time to first response was 56.5 days, or the first planned restaging cycle. Response durations 
are displayed graphically in Figure 1. The median duration of response (DOR) in patients 
with CR or PR was 13.8 months, while in patients with CR the median DOR was 19.3 
months. One patient with Sézary Syndrome remains in continuous CR 10+ years after first 
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remission. Another patient with CTCL was declared in CR after cycle 2; therapy was 
discontinued after 15 cycles and the patient was followed off-therapy for 33 months before 
discontinuing study still in remission.
Updated response durations in patients with PTCL are also shown in Table III and Figure 1, 
with the subset of patients with PTCL who had received ≥2 prior systemic chemotherapy 
regimens highlighted. The ORR in the total PTCL population was 38%, with 18% achieving 
a CR. Patients who received romidepsin in the third line or higher setting had an ORR of 
32%, with 16% achieving a CR, similar to the total population. Median durations of 
response were 9 and 8.4 months for all PTCL patients and for those who had received ≥2 
prior therapies, respectively. The median DOR for patients with CR in the total PTCL 
population was 74.1 months (Kaplan Meier plots included in Supplementary Figure 2). 
Additionally, ORR among the 19 patients who had received three or more prior regimens 
was 38%. Responses were also observed after bone marrow transplantation. In total, 18 
patients with PTCL had undergone prior bone marrow or stem cell transplant, either 
autologous or allogeneic; seven responses (38%) were observed in this patient 
subpopulation, including a CR in three patients and a PR in four patients.
Retreatment
Once the durability of responses following romidepsin treatment was recognized, 8 patients 
(5 CTCL, 3 PTCL) with excellent disease response had therapy with romidepsin suspended 
(Figure 2 and Supplementary Table 1). The patients remained on-study, but off treatment. 
Two patients never required retreatment and remain in CR (>10 years and >4 years). Six 
patients were re-treated due to disease flare occurring whilst off-therapy, after 43, 20.5 and 
7.4 months in three patients with CTCL and 56.1, 3.8 and 3.5 months in three patients with 
PTCL. In three patients, two with CTCL and one with PTCL, re-treatment offered 
substantial benefit. Photographs shown in Figure 3 were obtained from one patient with 
stage IV disease and circulating Sézary cells at enrollment who has received 3 separate 
courses of re-treatment, and is currently in remission 12 years after first enrollment. Another 
patient with partial remission received 72 cycles of continuous therapy before a break in 
therapy lasting 20 months before retreatment was required. Note that second and subsequent 
responses were not scored or included in calculations of response duration.
Adverse Events
Romidepsin is well tolerated with few grade 3 and 4 toxicities. As shown in Supplementary 
Tables 2A and 2B, the toxicity profile did show some variation between the CTCL and 
PTCL populations. Nausea was the most common side effect and was statistically more 
common in CTCL, occurring at least at one point in time in 81% (68/84) of patients with 
CTCL and 68% (32/47) of patients with PTCL despite prophylactic administration of 
antiemetics. Other gastrointestinal (GI) disturbances, including dysgeusia, vomiting and 
anorexia, appeared to be comparable between the two groups. Although GI disturbances 
were a common toxicity, fewer than 10% of patients experienced any episode of grade ≥3. 
Fatigue was comparably distributed between the two disease entities, occurring in 69% (58 
of 84) and 64% (30 of 47) of the CTCL and PTCL populations, respectively. 
Electrocardiogram (ECG) changes, including T wave flattening (grade 1) and ST segment 
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depression (grade 2), were commonly observed, although the clinical significance of these 
has not been determined (Cabell, et al 2009, Noonan, et al 2013).
We also examined the distribution of toxicities by severity grade. In this analysis, clearer 
differences emerged between the CTCL and the PTCL populations. A higher grade of 
thrombocytopenia was statistically more common in patients with PTCL, p = 0.0091; with a 
trend to greater severity in neutropenia also observed (P=0.030). These observations 
probably reflect the greater numbers of patients with prior cytotoxic therapies, including 
stem cell transplants. Fever was also more common in patients with PTCL, having been 
reported in 32% of patients with PTCL vs. 8.3% of patients with CTCL, and the severity of 
distribution was also greater for PTCL (p = 0.0015). We also noted elevated bilirubin, 
aspartate transaminase (AST) and alanine transaminase (ALT) more commonly in PTCL 
than in CTCL (p = 0.058, 0.020, and 0.0039, respectively) and attributed these to a cytokine 
release syndrome previously reported in PTCL (Teachey et al 2013; Staffolani et al 2012; 
Steinhoff et al 2008). This could also explain the trend toward greater severity of nausea in 
PTCL (p=0.045). One example of recurrent liver function test abnormalities in a patient with 
PTCL is shown in Figure 4. Viral re-activation was observed in three patients (Ritchie, et al 
2009) (2 with PTCL, one with CTCL) while on therapy; no additional cases were identified 
despite continued vigilance.
Off Study Reasons
Relatively few patients were removed from study for adverse events, shown in 
Supplementary Table 3. The most common reason for patients to be removed from study 
was disease progression in 63%. Adverse events accounted for 13 patients (10%) being 
removed from study and included fatigue, infection and viral reactivation. Seventeen 
patients (13%) discontinued study, six of them in order to obtain the drug in the community. 
There were 5 deaths (4%) on study; two with infection, one due to progression of disease 
and two sudden deaths within 24 h of romidepsin administration. Both of these patients had 
risk factors for sudden cardiac death – one with CTCL with pre-existing hypertrophic 
cardiac disease and significant valvular pathology, and one with PTCL with extensive 
atherosclerotic disease including prior myocardial infarction and vascular disease (Piekarz, 
et al 2009, Piekarz, et al 2011). One patient was removed from study due to worsening of 
pre-existing mitral valve disease that was not considered drug-related.
Correlative Studies
Correlative studies included measurement of histone acetylation and induction of the ABCB1 
(MDR1) gene as biomarkers of the epigenetic effect of romidepsin (Bates, et al 2010). There 
was a consistent increase in histone acetylation at 4 h, median 3-fold, which was resolving 
by 24 h. There was a modest correlation between serum romidepsin concentrations, 
persistence of histone acetylation at 24 h and response (Bates, et al 2010). RNA from paired 
samples from seven patients with significant CTCL blood involvement was analysed by 
cDNA microarrays; samples were obtained pre-infusion, at 4 h (at romidepsin infusion end) 
and 24 h (the day following romidepsin infusion) and subjected to analysis. A principal 
component analysis was performed on the 996 most variable genes. This analysis allowed us 
to see the underlying structure of the data and the major sources of variance. The gene 
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expression patterns were grouped by patient rather than by pre- or post-treatment sample 
(Figure 5A). This is further illustrated in Figure 5B, where unsupervised clustering of the 
996 most variable genes results in grouping of gene expression by patient rather than by 
relationship to treatment. However, when variation between patients was eliminated as a 
nominal factor by paired analysis (p<0.01, >2-fold change), 290 differentially expressed 
genes were identified: 175 at 4 h and 115 at 24 h. There was little in common (10 genes) 
between the data sets from the two time points, whether basal expression or gene induction 
was examined. Four patterns of gene expression change could be observed – “early” gene 
changes, with up- or down-regulation at 4 h, and “late” gene changes with up- or down-
regulation at 24 h (Figure 5C). Notably, most genes meeting the significance criteria at 4 h – 
whether induction or repression – demonstrated reversion by 24 h; and almost all genes 
meeting criteria at 24 h showed little change at the earlier time point. When Ingenuity 
Pathway Analysis (IPA) was used to assess gene expression changes, few pathways were 
observed in common (Figure 5D and Supplementary Table 4). However, a similar rapid 
reversion was observed in the identified pathways. One of the top networks identified was 
nuclear factor κB (NFκB), which has previously been shown to be down-regulated by 
HDAC inhibitors (Fabre, et al 2008, Takada, et al 2006). Effects on NFκB target genes are 
shown in the heat map in Figure 5E, with frequent reversal of the effect by 24 h.
Discussion
Initially identified by Fujisawa Pharmaceuticals in a screen for RAS-selective compounds, 
romidepsin was submitted to the NCI drug screen and selected for further development 
based on its unique profile in the NCI-60 cell line panel (Sandor, et al 2000). Although 
xenograft studies supported Phase I testing in solid tumours, limited activity was observed 
(Marshall, et al 2002, Sandor, et al 2002). However, we saw striking activity in a patient 
with PTCL, and then extended the trial to a cohort of 10 patients with CTCL or PTCL, 
where activity was again observed (Piekarz, et al 2001). This observation led to a Phase II 
trial in T-cell lymphoma conducted by the NCI’s intramural programme, as well as to the 
successful evaluation of other HDAC inhibitors in the treatment of T-cell lymphoma (Duvic, 
et al 2007, O'Connor, et al 2013, Olsen, et al 2007). GPI licensed romidepsin (subsequently 
licensed by Celgene Corporation) to complete its development, conducting separate pivotal 
trials for CTCL and PTCL. Data from both the NCI study and the GPI study supported 
regulatory submissions. The current report provides data on long-term responses in patients, 
the ability to retreat patients following recurrence off treatment, efficacy in the subset of 
patients with PTCL treated in third-line or later with romidepsin, and safety comparisons in 
the two populations.
Adverse event data for the entire study show that romidepsin toxicities are generally 
comparable in the two disease subtypes. The more frequent toxicities were fatigue, nausea 
and thrombocytopenia. Of note, there was a greater incidence of fever and liver enzyme and 
bilirubin elevation in PTCL than in CTCL, which may be related to a cytokine release 
syndrome that has been described in patients following T-cell activating therapies (Teachey, 
et al 2013), with chemotherapy in a patient with angioimmunoblastic T-cell lymphoma 
(Staffolani, et al 2012) and with vorinostat in a patient with CTCL (Steinhoff, et al 2008).
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Cardiac monitoring studies were previously reported, including a consistent small increase 
in heart rate, but a lack of myocardial damage or significant QT prolongation (Cabell, et al 
2009, Noonan, et al 2013, Piekarz, et al 2006). Electrolyte monitoring was added after the 
observation of six sudden deaths across several romidepsin trials, including two patients on 
the current trial. A clear relationship of romidepsin with these sudden deaths was not 
established because each patient had a pre-existing risk factor for sudden death. However, 
cardiac exclusion criteria were introduced, concomitant agents that would affect the QT 
interval were excluded, and potassium and magnesium monitoring was initiated. We 
recently reported that blood electrolyte levels met criteria for replacement in 55% of 1365 
doses reviewed and hypothesized that a gradient of romidepsin across the myocardial wall 
could cause altered expression or function of ATP-sensitive potassium channels, thereby 
altering repolarization time at different levels (Noonan, et al 2013). Sufficient potassium and 
magnesium levels would work to stabilize the effects of such a gradient and potentially 
prevent or reduce the magnitude of the ECG changes.
Although a biomarker that allowed enrichment of a subset of patients with a high probability 
of response could generate an increased response rate, such a marker has not yet been 
identified or validated. One potential biomarker being investigated is the expression of 
BCL2L11 (previously termed BIM), a pro-apoptotic protein that prevents anti-apoptotic 
proteins from sequestering BAX and BAK1 (previously termed BAK), components of the 
apoptotic machinery. Laboratory models suggest that reduced levels of BCL2L11 expression 
or any other alteration that interferes with intrinsic apoptosis is associated with resistance to 
romidepsin (Chakraborty, et al 2013, Ellis, et al 2009, Ierano, et al 2013, Newbold, et al 
2008) as well as other HDAC inhibitors (Lindemann, et al 2007). Until such a biomarker 
can be identified, it should be noted that the median time to response is 2 months, i.e., the 
first restaging visit, an indication that response does not take very long to declare itself and 
patients do not need to be exposed to long durations of treatment prior to determination of 
benefit.
PTCL is historically a disease with poor outcome, particularly in patients who relapse after 
initial therapy (O'Connor, et al 2014). An analysis of Canadian patients with PTCL 
receiving standard therapy after first relapse revealed a median overall survival (OS) of 5.5 
months and median progression-free survival (PFS) of 3.1 months , with those receiving 
chemotherapy at relapse having a median OS and PFS of 6.5 and 3.7 months, respectively 
(Mak, et al 2013). To evaluate efficacy in patients with poor prognosis, we analysed the 
results in those with heavily pretreated PTCL for whom romidepsin was third line therapy 
and showed that response rate in the third line setting was comparable to that observed in the 
whole PTCL population (Table IIIB). Although survival data were not collected in this 
study, responding patients exhibited long durations of response, suggesting a possible 
impact on survival. Similar observations were made in the GPI study (Coiffier, et al 2014). 
An ongoing Phase III study combining romidepsin with CHOP (cyclophosphamide, 
doxorubicin, vincristine, prednisone) (ClinicalTrials.gov Identifier: NCT01796002) will 
attempt to increase both response rates and survival; a lower romidepsin dose intensity in the 
combination is required, based on Phase I testing (Dupuis, et al 2012). An early report of 
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vorinostat and CHOP in combination for PTCL suggested a high response rate, with 12 of 
14 patients in CR and a median PFS of 31 months (Oki, et al 2013).
The marked benefit observed following romidepsin treatment in some patients with both 
CTCL and PTCL raises the inevitable question of the mechanism of action of romidepsin in 
T-cell lymphoma, and whether we can gain additional insights from the clinical and 
correlative data presented here. We can sum up the clinical data by observing that response 
to romidepsin occurs in just over a third of patients, and that it does not appear to be 
confined to a specific subgroup, at least based on histology. In circulating mononuclear cells 
containing malignant Sézary cells we clearly documented the induction of histone 
acetylation and gene expression - two cardinal manifestations of HDAC inhibition (Bates, et 
al 2010). However, these HDAC inhibitor effects were somewhat short-lived; acetylation 
was declining at 24 h. Examining the cDNA arrays obtained on samples from 7 patients, 
several notable features emerged. First, PCA plots demonstrated that there is little overlap 
among the patient samples. This was true not only in the post-treatment samples, but also at 
baseline. These baseline findings are consistent with previous reports showing differential 
gene expression clusters in both CTCL and PTCL (Piccaluga, et al 2013, Shin, et al 2007). 
Second, of the 16,000 genes on the Illumina array, only 290 were significantly altered when 
significance and variance filters with a paired t-test were used to identify statistically 
significant genes (p<0.01, >2-fold change), and only a few genes were altered in common 
between 4 h and 24 h. Among the genes being significantly altered, we found both those that 
were induced in accordance with the classical understanding of HDAC inhibitor action, and 
also a large number of genes whose expression was repressed (Ellis, et al 2008, Schrump, et 
al 2008). Moreover, levels of almost all of the genes induced or repressed at 4 h in the 
clinical samples were returning to baseline by 24 h. Among the 101 genes induced at 4 h, 
only 10 remained upregulated at 24 h. Among the 74 downregulated at 4 h, only 1 remained 
downregulated at 24 h. This was the most prominent feature of the dataset. As seen in the 
PCA plots, there was little overlap among the gene expression profiles – most of the 
variance was explained by patient-to patient variation rather than by the particular genes 
induced. These results are consistent with what others have reported, in that there are 
relatively few “genes in common” when datasets have been examined and no characteristic 
HDAC signature has been found to date, in our work or in that of others (Duvic, et al 2007, 
Ellis, et al 2008, LaBonte, et al 2009, Ma, et al 2013). When the arrays were subjected to 
IPA analysis, although some common pathways were observed, the top networks among the 
patients were different. These were puzzling aspects of the correlative data but matched the 
observations we have made in vitro. Not surprisingly, given the T-cell origin of the disease, 
immune-related pathways were modulated. The MAPK pathway was identified, a pathway 
that we and others previously noted to be modulated following HDAC inhibition 
(Chakraborty, et al 2013, Sarkar, et al 2011, Wozniak, et al 2010).
In addition, alterations in the NFκB pathway genes were identified, a pathway previously 
shown to be down-regulated by HDAC inhibitors (Bhalla, et al 2009, Chien, et al 2014, 
Fabre, et al 2008, Takada, et al 2006). Most studies showing reduction of NFκB pathway 
genes with HDAC inhibitors have used in vitro exposures of 24 – 48 h. The reversion of the 
effects of romidepsin on the NFκB pathway in the patient samples may be a consequence of 
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a shorter drug exposure due to drug clearance with a half-life of 2.5 – 3 h. Given that this 
pathway is known to promote survival (Van Waes 2007), a quick recovery could lead to 
restoration of pro-survival components. If proven valid, these observations support the 
development of combination approaches to sustain or extend the effects of romidepsin and 
possibly other HDAC inhibitors.
As a final approach to understanding the results in the clinical samples, we queried the 
L1000 dataset (http://www.lincscloud.org/l1000/), a catalog of gene expression profiles that 
are part of the LINCS (Library of integrated network-based cellular signatures, http://
www.lincsproject.org/) program and the Broad Connectivity MAP (CMAP) initiative. The 
LINCS data currently comprises +1.4 million gene expression profiles representing more 
than 20.000 small molecule compounds. Similar to the results obtained by Bolden et al 
(2013) in a gene expression profiling study of normal and transformed fibroblasts, the 
L1000 analysis identified multiple HDAC inhibitors with gene expression changes similar to 
those found in the 4-h treated patient samples (Supplementary Table 5). While the PCA plot 
primarily clustered samples according to patients (based on all data, not filtered for 
individual patient variation), removing the patient as a factor allowed the LINCS class-
enrichment to emerge. Thus, an understanding of the dominant mechanisms of HDAC 
inhibitor action require reconciliation of both the unique gene expression changes at the 
patient level and those pathways observed as HDAC inhibitor effects.
Our laboratory studies have shown that histone acetylation is ubiquitous, occurs consistently 
at multiple residues after HDAC inhibition, and is observed whether or not cell death 
follows (Luchenko, et al 2014). Likewise, the phase in the cell cycle where arrest occurs 
following HDAC inhibition is particular to the cell type rather than the particular HDAC 
inhibitor or drug dose. Our gene expression studies, both examining candidate gene markers 
of pharmacodynamic effects, the cDNA data shown here and xenograft data not shown here, 
demonstrate a biphasic response in many genes following romidepsin. This rapid reversal of 
HDAC inhibitor gene induction/inhibition, combined with the observation that few genes 
are regulated in common, as observed in our study and others (Duvic, et al 2007, Ellis, et al 
2008, LaBonte, et al 2009, Ma, et al 2013), argues against a mechanism of action dependent 
on a sustained gene expression programme, as classically understood for HDAC inhibitors. 
Conti et al (2010) reported that vorinostat-induced acetylation caused replication fork delays 
and double-strand DNA breaks. Gaymes et al. (2006) reported that in leukaemia cells, 
γH2AX, a marker of DNA double-strand breaks, occurred simultaneously with histone 
acetylation. These were observed early, before the onset of apoptosis. DNA damage as a 
dominant mechanism of action could explain some of the clinical observations, in particular, 
the lack of a sensitive subset that might be expected if there were a specific epigenetic lesion 
that was primarily targeted (Lemonnier, et al 2012, Palomero, et al 2014). Our in vitro work 
and that of others has shown that cell death is mediated via and dependent upon the intrinsic 
apoptotic pathway (Chakraborty, et al 2013, Chen, et al 2009, Ierano, et al 2013, Jóna, et al 
2011, Piekarz, et al 2004, Wiegmans, et al 2011). If this observation is correct, the 
combination of romidepsin with other agents that promote cell death via apoptotic pathways 
(Paoluzzi and O'Connor 2010) should increase the response rates and response durations, 
provided increases in toxicity do not require reduction of cancer drug doses. We postulate 
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that cells primed for apoptosis may respond with cell death to the massive global acetylation 
provoked by romidepsin and read as a DNA damage signal.
Finally, it should be noted that the observation of durable responses in a subset of patients 
provides evidence of the long-term safety of romidepsin and the absence of cumulative 
toxicity, including patients who have received multiple prior therapies. The long-term 
responses and safety data also support the study of romidepsin at an earlier stage of disease. 
One patient with Sézary Syndrome remains free of disease without relapse after 10 years. 
Despite its widening use in the clinic, important questions remain regarding romidepsin’s 
principal mechanisms of action and resistance, choice of agents for combination treatment 
and identification of a biomarker that would allow prior selection of patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported by the intramural programme of the National Institutes of Health, USA, and by a CRADA 
with Celgene Corporation. The authors would also like to acknowledge individuals in the Cancer Therapy 
Evaluation Program (CTEP) for their participation in the sponsorship of this trial and the editorial assistance of Rob 
Robey.
Susan E. Bates designed research, performed research, analysed data and wrote the paper; Robin Eisch performed 
research and analysed data; Alex Ling performed research and analysed data; Douglas Rosing performed research 
and analysed data; Maria Turner performed research; Stefania Pittaluga performed research; H. Miles Prince 
performed research, wrote the paper and analysed data; Mark H. Kirschbaum performed research, wrote the paper 
and analysed data; Steve Allen performed research, wrote the paper and analysed data; Jasmine Zain performed 
research; Larisa J. Geskin performed research; David Joske performed research; Leslie Poppelwell performed 
research; Edward Cowen performed research; Elaine S. Jaffe performed research; Jean Nichols analysed data; Sally 
Kennedy analysed data; Seth M. Steinberg analysed data; David J. Liewehr analysed data; Louise C. Showe 
performed research and analysed data; Thomas Litman analysed data and contributed vital tools; Caryn Steakley 
performed research and analysed data; John Wright designed research and contributed vital tools; Tito Fojo 
performed research, and wrote the paper; Richard L. Piekarz analysed data, performed research, wrote the paper 
and designed research.
References
Bates S, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey R, Turner M, Gardner E, Figg 
W, Steinberg S, Ling A, Fojo T, To K, Piekarz R. Laboratory correlates for a phase II trial of 
romidepsin in cutaneous and peripheral T-cell lymphoma. British Journal of Haematology. 2010; 
148:256–267. [PubMed: 19874311] 
Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, 
Gordon LI, Evens AM. PCI-24781 induces caspase and reactive oxygen species-dependent 
apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. 
Clinical Cancer Research. 2009; 15:3354–3365. [PubMed: 19417023] 
Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone 
RW. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell 
Death and Disease. 2013; 4:e519. [PubMed: 23449455] 
Cabell C, Bates S, Piekarz R, Whittaker S, Kim YH, Currie M, Godfrey CJ, Schoonmaker C, Nichols 
J, Nix D, Burris HA. Systematic Assessment of Potential Cardiac Effects of the Novel Histone 
Deacetylase (HDAC) Inhibitor Romidepsin. Blood (American Society of Hematology Annual 
Meeting Abstracts). 2009; 114:3709.
Bates et al. Page 12
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from 
distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010; 
116:767–771. [PubMed: 20484084] 
Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, 
Wilkerson J, Showe LC, Gottesman MM, Collie NL, Bates SE. MAPK pathway activation leads to 
Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an 
MEK inhibitor. Blood. 2013; 121:4115–4125. [PubMed: 23532732] 
Chen S, Dai Y, Pei X, Grant S. Bim upregulation by histone deacetylase inhibitors mediates 
interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and 
Mcl-1. Molecular and Cellular Biology. 2009; 29:6149–6169. [PubMed: 19805519] 
Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J, Lister T, Vose J, Grillo-López A, 
Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris N, Armitage J, 
Carter W, Hoppe R, Canellos G. Report of an international workshop to standardize response 
criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of 
Clinical Oncology. 1999; 17:1244. [PubMed: 10561185] 
Chien W, Lee DH, Zheng Y, Wuensche P, Alvarez R, Wen DL, Aribi AM, Thean SM, Doan NB, Said 
JW, Koeffler HP. Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor 
belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in 
vitro and in vivo. Molecular Carcinogenesis. 2014; 53:722–735. [PubMed: 23475695] 
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, 
Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, 
Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in 
relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of Clinical 
Oncology. 2012; 30:631–636. [PubMed: 22271479] 
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm 
M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, 
Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: 
pivotal study update demonstrates durable responses. Journal of Hematology & Oncology. 2014; 
7:11. [PubMed: 24456586] 
Conti C, Leo E, Eichler GS, Sordet O, Martin MM, Fan A, Aladjem MI, Pommier Y. Inhibition of 
histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and 
induces DNA damage. Cancer Research. 2010; 70:4470–4480. [PubMed: 20460513] 
Dupuis J, Casasnovas RO, Ghesquieres H, Morschhauser F, Tilly H, Thieblemont C, Ribrag V, 
Coiffier B. A Phase Ib Trial of Romidepsin in Association with CHOP in Patients with Peripheral 
T-Cell Lymphoma (PTCL): The Ro-CHOP Study. Blood (American Society of Hematology 
Annual Meeting Abstracts). 2012; 120:1617.
Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao J, Reilly J, Ricker J, Richon V, 
Frankel S. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory 
cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109:31–39. [PubMed: 16960145] 
Ellis L, Pan Y, Smyth G, George D, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, 
Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone R, Prince H. Histone deacetylase 
inhibitor panobinostat induces clinical responses with associated alterations in gene expression 
profiles in cutaneous T-cell lymphoma. Clinical Cancer Research. 2008; 14:4500–4510. [PubMed: 
18628465] 
Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, 
Lowe SW, Johnstone RW. The histone deacetylase inhibitors LAQ824 and LBH589 do not require 
death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic 
efficacy. Blood. 2009; 114:380–393. [PubMed: 19383971] 
Fabre C, Grosjean J, Tailler M, Boehrer S, Adès L, Perfettini JL, de Botton S, Fenaux P, Kroemer G. 
A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition 
in malignant myeloblasts. Cell Cycle. 2008; 7:2139–2145. [PubMed: 18641459] 
Ferrara G, Pancione M, Votino C, Quaglino P, Tomasini C, Santucci M, Pimpinelli N, Cusano F, 
Sabatino L, Colantuoni V. A specific DNA methylation profile correlates with a high risk of 
disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. British Journal of 
Dermatology. 2013; 170:1266–1275. [PubMed: 24641245] 
Bates et al. Page 13
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Frye R, Myers M, Axelrod KC, Ness EA, Piekarz RL, Bates SE, Booher S. Romidepsin: a new drug 
for the treatment of cutaneous T-cell lymphoma. Clinical Journal of Oncology Nursing. 2012; 
16:195–204. [PubMed: 22459529] 
Gaymes TJ, Padua RA, Pla M, Orr S, Omidvar N, Chomienne C, Mufti GJ, Rassool FV. Histone 
deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-
specific HDI-dependent apoptosis? Molecular Cancer Research. 2006; 4:563–573. [PubMed: 
16877702] 
Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE. 
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid 
tumors. Expert Review of Anticancer Therapy. 2010; 10:997–1008. [PubMed: 20645688] 
Ierano C, Chakraborty AR, Nicolae A, Bahr JC, Zhan Z, Pittaluga S, Bates SE, Robey RW. Loss of the 
proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors. Cell Cycle. 
2013; 12:2829–2838. [PubMed: 23966164] 
Jóna A, Khaskhely N, Buglio D, Shafer JA, Derenzini E, Bollard CM, Medeiros LJ, Illés A, Ji Y, 
Younes A. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin 
lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental Hematology. 2011; 
39:1007–1017. e1001. [PubMed: 21767511] 
LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of 
genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in 
colon cancer cell lines. BMC Medical Genomics. 2009; 2:67. [PubMed: 19948057] 
Lemonnier F, Couronné L, Parrens M, Jaïs JP, Travert M, Lamant L, Tournillac O, Rousset T, Fabiani 
B, Cairns RA, Mak T, Bastard C, Bernard OA, de Leval L, Gaulard P. Recurrent TET2 mutations 
in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. 
Blood. 2012; 120:1466–1469. [PubMed: 22760778] 
Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, 
Dear AE, Scott CL, Pellegrini M, Wei A, Richon VM, Marks PA, Lowe SW, Smyth MJ, 
Johnstone RW. Analysis of the apoptotic and therapeutic activities of histone deacetylase 
inhibitors by using a mouse model of B cell lymphoma. Proceedings of the National Academy of 
Science U S A. 2007; 104:8071–8076.
Luchenko VL, Litman T, Chakraborty AR, Heffner A, Devor C, Wilkerson J, Stein W, Robey RW, 
Bangiolo L, Levens D, Bates SE. Global histone changes induced by romidepsin and vorinostat do 
not explain apoptosis—a study of cell context-specific effects. Molecular Oncology. 2014
Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, 
Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, Freemantle SJ, 
Dragnev KH, Dmitrovsky E. Comparing histone deacetylase inhibitor responses in genetically 
engineered mouse lung cancer models and a window of opportunity trial in patients with lung 
cancer. Molecular Cancer Therapeutics. 2013; 12:1545–1555. [PubMed: 23686769] 
Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM, 
Savage KJ. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: 
spectrum of disease and rare long-term survivors. Journal of Clinical Oncology. 2013; 31:1970–
1976. [PubMed: 23610113] 
Marshall J, Rizvi N, Kauh J, Dahut W, Figuera M, Kang M, Figg W, Wainer I, Chaissang C, Li M, 
Hawkins M. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. Journal 
of Experimental Therapeutics and Oncology. 2002; 2:325–332. [PubMed: 12440223] 
McKenzie RC, Jones CL, Tosi I, Caesar JA, Whittaker SJ, Mitchell TJ. Constitutive activation of 
STAT3 in Sézary syndrome is independent of SHP-1. Leukemia. 2012; 26:323–331. [PubMed: 
21818116] 
Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, Johnstone RW. Characterisation of 
the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. 
Molecular Cancer Therapeutics. 2008; 7:1066–1079. [PubMed: 18483296] 
Noonan AM, Eisch RA, Liewehr DJ, Sissung TM, Venzon D, Flagg TP, Haigney MC, Steinberg SM, 
Figg WD, Piekarz RL, Bates SE. Electrocardiographic Studies of Romidepsin Demonstrate Its 
Safety and Identify a Potential Role for the KATP channel. Clinical Cancer Research. 2013; 
19:3095–3104. [PubMed: 23589175] 
Bates et al. Page 14
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
O'Connor O, Masszi T, Savage K, Pinter-Brown L, Foss F, Popplewell L, Cashen A, Doorduijn J, 
Chawla S, Knoblauch P, Zinzani P, Brown P, Hess G, Van Hoof A, Horwitz S, Shustov A. 
Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral 
T-cell lymphoma (R/R PTCL): Results from the BELIEF trial. Journal of Clinical Oncology. 
2013; 31(suppl):abstr 8507.
O'Connor OA, Bhagat G, Ganapathi K, Pedersen MB, D'Amore F, Radeski D, Bates SE. Changing the 
paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice. Clinical 
Cancer Research. 2014; 20:5240–5254. [PubMed: 25320373] 
Oki Y, Younes A, Copeland A, Hagemeister F, Fayad LE, McLaughlin P, Shah J, Fowler N, 
Romaguera J, Kwak LW, Pro B. Phase I study of vorinostat in combination with standard CHOP 
in patients with newly diagnosed peripheral T-cell lymphoma. British Journal of Haematology. 
2013; 162:138–141. [PubMed: 23590726] 
Olsen E, Kim Y, Kuzel T, Pacheco T, Foss F, Parker S, Frankel S, Chen C, Ricker J, Arduino J, Duvic 
M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment 
refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology. 2007; 25:3109–3115. 
[PubMed: 17577020] 
Palomero T, Couronné L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter 
Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, Balbin M, Bastard C, Bhagat 
G, Piris MA, Campo E, Bernard OA, Rabadan R, Ferrando AA. Recurrent mutations in epigenetic 
regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature Genetics. 2014; 
46:166–170. [PubMed: 24413734] 
Paoluzzi L, O'Connor OA. Targeting survival pathways in lymphoma. Advances in Experimental 
Medicine and Biology. 2010; 687:79–96. [PubMed: 20919639] 
Piccaluga PP, Fuligni F, De Leo A, Bertuzzi C, Rossi M, Bacci F, Sabattini E, Agostinelli C, Gazzola 
A, Laginestra MA, Mannu C, Sapienza MR, Hartmann S, Hansmann ML, Piva R, Iqbal J, Chan 
JC, Weisenburger D, Vose JM, Bellei M, Federico M, Inghirami G, Zinzani PL, Pileri SA. 
Molecular profiling improves classification and prognostication of nodal peripheral T-cell 
lymphomas: results of a phase III diagnostic accuracy study. Journal of Clinical Oncology. 2013; 
31:3019–3025. [PubMed: 23857971] 
Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, 
Altemus R, Bates SE. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the 
treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001; 98:2865–
2868. [PubMed: 11675364] 
Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S, Bates SE. T-cell 
lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of 
depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 
2004; 103:4636–4643. [PubMed: 14996704] 
Piekarz RL, Frye AR, Wright JJ, Steinberg SM, Liewehr DJ, Rosing DR, Sachdev V, Fojo T, Bates 
SE. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell 
lymphoma. Clinical Cancer Research. 2006; 12:3762–3773. [PubMed: 16778104] 
Piekarz R, Frye R, Turner M, Wright J, Allen S, Kirschbaum M, Zain J, Prince H, Leonard J, Geskin 
L, Reeder C, Joske D, Figg W, Gardner E, Steinberg S, Jaffe E, Stetler-Stevenson M, Lade S, Fojo 
A, Bates S. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as 
monotherapy for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology. 2009; 
27:5410–5417. [PubMed: 19826128] 
Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer 
CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, 
Bates SE. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011; 
117:5827–5834. [PubMed: 21355097] 
Ritchie D, Piekarz R, Blombery P, Karai L, Pittaluga S, Jaffe E, Raffeld M, Janik J, Prince H, Bates S. 
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case 
series report. Haematologica. 2009; 94:1618–1622. [PubMed: 19608677] 
Robbins AR, Jablonski SA, Yen TJ, Yoda K, Robey R, Bates SE, Sackett DL. Inhibitors of histone 
deacetylases alter kinetochore assembly by disrupting pericentromeric heterochromatin. Cell 
Cycle. 2005; 4:717–726. [PubMed: 15846093] 
Bates et al. Page 15
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Robert C, Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Advances in Cancer 
Research. 2012; 116:87–129. [PubMed: 23088869] 
Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE, Sackett DL. FR901228 causes 
mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs. 2000; 11:445–454. 
[PubMed: 11001385] 
Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, 
Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE. Phase I Trial of the 
Histone Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in Patients with 
Refractory Neoplasms. Clinical Cancer Research. 2002; 8:718–728. [PubMed: 11895901] 
Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV. Histone deacetylase inhibitors 
reverse CpG methylation by regulating DNMT1 through ERK signaling. Anticancer Research. 
2011; 31:2723–2732. [PubMed: 21868513] 
Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, 
Kruchin E, Wright JJ, Rosing DR, Sparreboom A, Figg WD, Steinberg SM. Clinical and 
molecular responses in lung cancer patients receiving Romidepsin. Clinical Cancer Research. 
2008; 14:188–198. [PubMed: 18172270] 
Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W, Yao YM, Kwon P, Fawell S, Atadja P. 
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: 
Defining molecular mechanisms of resistance. International Journal of Cancer. 2010; 127:2199–
2208.
Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, Kupper TS. Lesional gene expression 
profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. 
Blood. 2007; 110:3015–3027. [PubMed: 17638852] 
Shiraga T, Tozuka Z, Ishimura R, Kawamura A, Kagayama A. Identification of cytochrome P450 
enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human 
liver microsomes. Biological and Pharmaceutical Bulletin. 2005; 28:124–129. [PubMed: 
15635176] 
Staffolani E, Nicolais R, Manca di Villahermosa S, Galli D, Postorino M, Di Daniele N. Cytokine 
removal under hemodiafiltration with endogenous reinfusion in acute kidney injury secondary to 
angioimmunoblastic T-cell lymphoma: a case report. Blood Purification. 2012; 34:349–353. 
[PubMed: 23344085] 
Steinhoff M, Beyer M, Roewert-Huber J, Lukowsky A, Assaf C, Sterry W. Complete clinical 
remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous 
reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. Journal 
of the American Academy of Dermatology. 2008; 58:S88–91. [PubMed: 18489056] 
Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates 
apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-
kappaB activation. Journal of Biological Chemistry. 2006; 281:5612–5622. [PubMed: 16377638] 
Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, 
Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after 
blinatumomab treatment related to abnormal macrophage activation and ameliorated with 
cytokine-directed therapy. Blood. 2013; 121:5154–5157. [PubMed: 23678006] 
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van 
Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the 
response to treatment in solid tumors. European Organization for Research and Treatment of 
Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. 
Journal of the National Cancer Institute. 2000; 92:205–16. [PubMed: 10655437] 
Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, Hodges E, Vermeer M, Packham 
G. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression 
in cutaneous T-cell lymphoma cells. British Journal of Pharmacology. 2011; 162:1590–1602. 
[PubMed: 21198545] 
Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clinical 
Cancer Research. 2007; 13:1076–1082. [PubMed: 17317814] 
Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, 
Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, 
Bates et al. Page 16
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Journal of Clinical 
Oncology. 2010; 28:4485–4491. [PubMed: 20697094] 
Wiegmans AP, Alsop AE, Bots M, Cluse LA, Williams SP, Banks KM, Ralli R, Scott CL, Frenzel A, 
Villunger A, Johnstone RW. Deciphering the Molecular Events Necessary for Synergistic Tumor 
Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic 
ABT-737. Cancer Research. 2011; 71:3603–3615. [PubMed: 21398407] 
Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martínez Leal JF, de La Cueva P, Rodriguez 
ME, Herreros B, Martin-Perez D, Longo MI, Herrera M, Piris MA, Ortiz-Romero PL. Vorinostat 
interferes with the signaling transduction pathway of T-cell receptor and synergizes with 
phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica. 2010; 
95:613–621. [PubMed: 20133897] 
Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase 
inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic 
action. Journal of Investigative Dermatology. 2005; 125:1045–1052. [PubMed: 16297208] 
Bates et al. Page 17
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Durations of response for patients with CTCL and PTCL. Durations in patients with CR are 
shown in dark grey, and patients with PR shown in lighter grey. *Indicates patients censored 
at data cut-off still in CR or censored at off study date still in response continuing 
romidepsin. Patients with PTCL who received romidepsin in third-line (with two or more 
prior chemotherapy regimens before enrollment) are indicated by the hatched bars. CTCL, 
cutaneous T-cell lymphoma; PTCL, peripheral T-cell lymphoma; CR, complete response; 
PR, partial response.
Bates et al. Page 18
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Graphical display of treatment durations and intervals in patients who had treatment breaks. 
On-treatment interval is shown in dark grey, while the hatched areas show off-treatment 
interval. * Indicates that response was continuing at the time of data cut-off or study 
discontinuation. One patient with CTCL discontinued study to receive romidepsin at home 
after US Food and Drug Administration approval of the agent. CTCL, cutaneous T-cell 
lymphoma; PTCL, peripheral T-cell lymphoma.
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Figure 3. 
Patient with Stage IVA cutaneous T-cell lymphoma (CTCL) diagnosed 22 months prior to 
study entry. Prior therapies included 2 months of psoralen photochemotherapy, 3 months of 
denileukin diftitox, 2 months of pentostatin and 5 months of liposomal doxorubicin. She 
presented at age 64 years with stage IVA disease, with skin involvement, enlarged lymph 
nodes, and circulating malignant cells. After 2 cycles of romidepsin, this patient achieved a 
partial response, and a complete response was scored at the end of Cycle 9. At Cycle 20, a 
single small patch was noted on her sacral area that was biopsied and confirmed for CTCL 
cells. As per protocol, disease progression was called, but romidepsin was continued as 
compassionate use. Small patch disease waxed and waned over the next 12 cycles. A 
decision was made to stop romidepsin after a total 32 cycles, and the patient was followed 
without progression another 43 months. She then presented with generalized erythroderma, 
increased circulating Sézary cells in her blood, and enlargement of lymph nodes. She began 
a 6-cycle course of romidepsin that cleared blood and skin. She was again monitored for 34 
months without treatment, after which increasing disease in skin and blood prompted 
another 6-cycle course of romidepsin, with clearing of disease. She was monitored off 
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therapy an additional 14 months until disease required re-initiation of another course of 
romidepsin, completed 12 years after her original enrollment on NCI1312. This course is 
summarized as Patient 1 in Supplementary Table 1. C, cycle; D, day
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Figure 4. 
Bilirubin, ALT and AST elevation following romidepsin. Patient with PTCL (subtype PTCL 
not otherwise specified) previously treated with cyclophosphamide, doxorubicin, vincristine 
and prednisone (CHOP). The patient’s medical history was notable for fever, chills and 
abdominal pain, and baseline symptoms included lymphopenia, elevated alkaline 
phosphatase, elevated ALT and AST, hypoalbuminaemia, and hypocalcaemia. The patient 
started treatment with romidepsin 14 mg/m2 and received a total of 39 romidepsin doses in 
13 cycles with a last dose of romidepsin on C13D15, when disease progression was noted. 
During the early cycles, ALT and AST increased markedly after the first dose of each cycle, 
and increases in bilirubin were almost always noted the day after romidepsin infusion. 
PTCL, peripheral T-cell lymphoma; ALT, alanine transaminase; AST, aspartate 
transaminase
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Figure 5. 
cDNA microarray analysis performed on 0h, 4h, and 24h samples in 7 patients with 
circulating Sézary cells.
A. Principal component analysis (PCA) plot based on the 996 most variable genes (Filtered 
by variance: σ/σmax>0.3) across all samples. The 20 samples are coloured according to 
patient number.
B. Heat-map and unsupervised hierarchical clustering based on the same 996 most variable 
genes as for the PCA plot. Again, we see clear clustering according to individual patients, 
rather than according to time. The 4h sample for Patient 7 was eliminated as an outlier. 
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Green shading indicates reduction in gene expression and red shading indicates an increase 
in gene expression.
C. Heat-map and one-way hierarchical clustering based on the 290 genes that differed 
between 4h and 0h, and between 24h and 0h identified by a paired analysis eliminating 
patient as a nominal factor (p<0.01, >2-fold change). As seen, changes at 4h typically 
reverse by 24h, and changes at 24h were seldom seen at 4h. Only 10 genes were found in 
common between the two time comparisons. Expanded heat maps including gene names can 
be found in Supplementary Figure 3.
D. Bubble diagram showing the top-14 canonical pathways over-represented in the 
transcriptome of the 6 patients (P1-6) at times 4h and 24h post-treatment. The colour 
indicates the p-value (calculated by the right-tailed Fisher Exact Test*) for each particular 
pathway; from dark red (P<0.00001) to pale (not significant). The size of each bubble 
indicates the ratio, which is the number of genes in a given pathway that meet the cut-off 
criteria divided by the total number of genes that make up that pathway. The larger and 
darker a given bubble, the more significant the finding. *The details of the calculation of the 
P-value can be found in this whitepaper: http://www.ingenuity.com/wp-content/themes/
ingenuity-qiagen/pdf/ipa/functions-pathways-pval-whitepaper.pdf
E. Ingenuity Pathway Analysis identified NFκB as one of the top altered networks at the 4 h 
time-point. Shown are the changes in NFκB targets at 4 and 24 h. Heat-map and 2-way 
hierarchical clustering based on 29 NF-κB target genes that differ significantly (p<0.05) 
between time points. Patient is eliminated as a nominal factor. Target genes of NF-κB were 
obtained from the NF-κB online resource at Boston University: http://www.bu.edu/nf-kb/
gene-resources/target-genes/.
Bates et al. Page 24
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Bates et al. Page 25
Ta
bl
e 
1
Pa
tie
nt
 D
em
og
ra
ph
ic
s a
nd
 C
lin
ic
al
 C
ha
ra
ct
er
ist
ic
s
C
TC
L
N
 =
 8
4
PT
C
L
N
 =
 4
7
Pa
tie
nt
s (
n)
%
Pa
tie
nt
s (
n)
%
Se
x
M
al
e
57
68
%
25
53
%
Fe
m
al
e
27
29
%
22
47
%
A
ge
, y
ea
rs
M
ed
ia
n
59
59
R
an
ge
28
–8
4
27
–8
4
<
50
32
8
≥5
0
52
39
D
ise
as
e 
st
ag
e 
at
 ti
m
e 
of
 e
nr
ol
lm
en
t
I
7
8%
0
0%
IA
1
IB
6
II
21
25
%
2
4%
II
A
3
II
B
18
II
I
6
7%
11
23
%
II
IA
3
II
IB
3
IV
49
58
%
34
72
%
IV
A
32
IV
B
17
EC
O
G
 p
er
fo
rm
an
ce
 st
at
us
0
24
29
%
20
43
%
1
49
58
%
23
49
%
2
11
13
%
4
8%
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Bates et al. Page 26
C
TC
L
N
 =
 8
4
PT
C
L
N
 =
 4
7
Pa
tie
nt
s (
n)
%
Pa
tie
nt
s (
n)
%
El
ev
at
ed
 L
D
H
35
 o
f 8
1
43
%
18
 o
f 3
5
51
%
Lo
w
 a
lb
um
in
43
 o
f 8
1
53
%
18
 o
f 3
5
51
%
N
o.
 p
ri
or
 th
er
ap
ie
s*
M
ed
ia
n
3
3
R
an
ge
0–
14
1–
11
Pr
ev
io
us
 to
pi
ca
l t
he
ra
pi
es
48
57
%
1
PU
V
A
43
51
%
1
To
pi
ca
l N
M
17
20
%
0
To
pi
ca
l b
ex
ar
ot
en
e
5
6%
0
To
pi
ca
l s
te
ro
id
s
13
16
%
0
U
V
B
1
1%
0
Pr
ev
io
us
 r
ad
ia
tio
n 
th
er
ap
y†
44
52
%
0
Ex
te
rn
al
 B
ea
m
 R
T
17
36
%
Lo
ca
liz
ed
 ra
di
ot
he
ra
py
36
43
%
0
TS
EB
T
13
15
%
0
Pr
ev
io
us
 e
xt
ra
co
rp
or
ea
l
19
23
%
0
Pr
ev
io
us
 sy
st
em
ic
, n
on
-c
yt
ot
ox
ic
 th
er
ap
ie
s
55
65
%
14
30
%
In
te
rfe
ro
n
28
33
%
3
6%
D
en
ile
uk
in
 d
ift
ito
x
15
18
%
1
2%
A
le
m
tu
zu
m
ab
4
5%
0
A
nt
i-T
ac
 a
nt
ib
od
y
5
6%
0
O
ra
l c
or
tic
os
te
ro
id
s
19
23
%
7
15
%
R
et
in
oi
d:
 o
ra
l b
ex
ar
ot
en
e
37
44
%
3
6%
R
et
in
oi
d:
 o
th
er
 ‡
10
12
%
0
V
or
in
os
ta
t
4
5%
0
Pr
ev
io
us
 sy
st
em
ic
 c
he
m
ot
he
ra
py
R
eg
im
en
s §
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Bates et al. Page 27
C
TC
L
N
 =
 8
4
PT
C
L
N
 =
 4
7
Pa
tie
nt
s (
n)
%
Pa
tie
nt
s (
n)
%
0
32
38
%
0
1
25
30
%
16
34
%
2
15
18
%
10
21
%
>
2
12
14
%
21
45
%
*
O
th
er
 tr
ea
tm
en
ts 
no
t l
ist
ed
 in
cl
ud
e 
cy
cl
os
po
rin
e,
 ta
cr
ol
im
us
, a
za
th
io
pr
in
e,
 re
m
ic
ad
e,
 p
el
de
sin
e,
 a
nd
 d
en
dr
iti
c 
ce
ll 
va
cc
in
e
† S
om
e 
pa
tie
nt
s h
ad
 b
ot
h 
lo
ca
liz
ed
 ra
di
at
io
n 
th
er
ap
y 
(R
T)
 an
d t
ota
l s
kin
 el
ec
tro
n b
ea
m 
the
rap
y (
TS
EB
).
‡ I
nc
lu
de
s o
ra
l b
ex
ar
ot
en
e 
an
d 
in
te
rfe
ro
n 
in
 c
om
bi
na
tio
n
§ C
he
m
ot
he
ra
pi
es
 in
cl
ud
e 
m
on
ot
he
ra
pi
es
 su
ch
 a
s g
em
ci
ta
bi
ne
 a
nd
 m
et
ho
tre
xa
te
, a
nd
 c
om
bi
na
tio
n 
th
er
ap
ie
s s
uc
h 
as
 C
H
O
P 
(cy
clo
ph
os
ph
am
ide
, d
ox
oru
bic
in,
 vi
nc
ris
tin
e, 
pre
dn
iso
ne
), I
CE
 (i
fos
fam
ide
, 
ca
rb
op
la
tin
, e
to
po
sid
e),
 C
VA
D 
(cy
clo
ph
os
ph
am
ide
, v
inc
ris
tin
e, 
do
xo
rub
ici
n, 
de
xa
me
tha
so
ne
), E
PO
CH
 (e
top
os
ide
, v
inc
ris
tin
e, 
do
xo
rub
ici
n, 
cy
clo
ph
os
ph
am
ide
, p
red
nis
on
e),
 in
ter
fer
on
 an
d b
ex
aro
ten
e, 
m
et
ho
tre
xa
te
 a
nd
 g
em
ci
ta
bi
ne
, a
nd
 fl
uo
ro
ur
ac
ilw
ith
 in
tra
le
sio
na
l i
nje
cti
on
.
EC
O
G
, E
as
te
rn
 C
oo
pe
ra
tiv
e 
O
nc
ol
og
y 
G
ro
up
; L
D
H
, l
ac
ta
te
 d
eh
yd
ro
ge
na
se
; P
U
V
A
, p
so
ra
le
n 
ph
ot
oc
he
m
ot
he
ra
py
; N
M
, n
itr
og
en
 m
us
ta
rd
; U
V
B,
 u
ltr
a-
vi
ol
et
 B
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Bates et al. Page 28
Ta
bl
e 
II
A
dm
in
ist
er
ed
 T
he
ra
py
TO
TA
L
C
TC
L
PT
C
L
N
 =
 1
31
N
=8
4
N
=4
7
To
ta
l n
um
be
r 
of
 c
yc
le
s
12
14
74
9
46
5
C
yc
le
s p
er
 p
at
ie
nt
, n
um
be
r o
f c
yc
le
s
 
M
ed
ia
n
4.
5
3
 
R
an
ge
1 
to
 8
3
1 
to
 7
9
1 
to
 8
3
C
yc
le
s p
er
 p
at
ie
nt
, n
um
be
r o
f p
at
ie
nt
s
 
≤ 
2
36
14
22
 
3 
to
 5
43
34
9
 
≥ 
6
52
36
16
D
os
es
 p
er
 p
at
ie
nt
 (n
)
 
M
ed
ia
n
12
.5
9
 
R
an
ge
1 
to
 2
47
2 
to
 1
58
1 
to
 2
47
D
os
es
 p
er
 p
at
ie
nt
 (n
)
 
To
ta
l d
os
es
34
04
20
68
13
36
 
 
Fu
ll 
do
se
22
79
67
%
15
88
77
%
69
1
52
%
 
 
D
os
e 
es
ca
la
te
d
28
6
8%
15
1
7%
13
5
10
%
 
 
R
ed
uc
ed
, t
ot
al
83
9
25
%
32
9
16
%
51
0
38
%
 
 
Fi
rs
t d
os
e 
re
du
ct
io
n 
(fr
om
 im
me
dia
te 
pri
or 
do
se)
20
9
6%
64
3%
14
5
11
%
CT
CL
, c
ut
an
eo
us
 T
-c
el
l l
ym
ph
om
a;
 P
TC
L,
 p
er
ip
he
ra
l T
-c
el
l l
ym
ph
om
a.
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Bates et al. Page 29
Ta
bl
e 
III
R
om
id
ep
sin
 e
ffi
ca
cy
 in
 C
TC
L 
an
d 
PT
CL
 p
op
ul
at
io
ns
Pa
tie
nt
s w
ith
 C
TC
L
Pa
tie
nt
s w
ith
 P
TC
L
R
es
po
ns
e
(N
=8
4)
(N
=4
5)
≥2
 p
ri
or
 th
er
ap
ie
s (
N 
= 3
1)
n
 (%
)
n
 (%
)
n
 (%
)
C
R
 +
 P
R
28
 (3
3%
)
17
 (3
8%
)
10
 (3
2%
)
CR
5 
(6%
)
8 
(18
%)
5 
(16
%)
PR
23
 (2
7%
)
9 
(20
%)
5 
(16
%)
SD
32
 (3
8%
)
5 
(11
%)
5 
(16
%)
PD
18
 (2
2%
)
18
 (4
0%
)
12
 (3
9%
)
N
E
6 
(7%
)
5 
(11
%)
4 
(13
%)
M
ed
ia
n 
D
O
R
C
R
/P
R
13
.8
 m
on
th
s (
1 –
 12
7+
)
9 
m
on
th
s (
2 –
 76
+)
8.
4 
m
on
th
s (
3 –
 74
)
C
R
19
.3
 m
on
th
s (
8 –
 12
7+
)
74
 m
on
th
s (
3 –
 76
+)
74
 m
on
th
s (
6 –
 74
)
CT
CL
, c
ut
an
eo
us
 T
-c
el
l l
ym
ph
om
a;
 P
TC
L,
 p
er
ip
he
ra
l T
-c
el
l l
ym
ph
om
a;
 C
R,
 c
om
pl
et
e 
re
sp
on
se
; P
R,
 p
ar
tia
l r
es
po
ns
e;
 S
D
, s
ta
bl
e 
di
se
as
e;
 P
D
, p
ro
gr
es
siv
e 
di
se
as
e;
 N
E,
 n
ot
 e
va
lu
ab
le
; D
O
R,
 d
ur
at
io
n 
of
 
re
sp
on
se
 (d
efi
ne
d a
s t
he
 tim
e f
rom
 fi
rst
 re
co
rde
d r
esp
on
se 
to 
pro
gre
ssi
on
 of
 di
sea
se 
or 
ce
ns
ori
ng
 da
te)
Br J Haematol. Author manuscript; available in PMC 2016 July 01.
